The Medicines Company (MDCO)

Company Description

The Medicines Company provides medical solutions for patients in acute and intensive care hospitals worldwide. The company markets Angiomax, an intravenous direct thrombin inhibitor used as an anticoagulant in cardiovascular events such PTCA and stenting; Recothrom, a human recombinant thrombin used as an aid to hemostasis; Cleviprex, an intravenous small molecule calcium channel blocker for blood pressure reduction; and ready-to-use formulation of Argatroban for the treatment of thrombosis. Its products under development include Cangrelor, an intravenous small molecule antiplatelet agent that is Phase III clinical trial for the prevention of platelet activation; Oritavancin, an investigational intravenous antibiotic, which is in Phase III clinical trials for the treatment of acute bacterial infections; and IONSYS, a pre-registration stage product for the short-term management of acute postoperative pain. Products under development include MDCO-216, a novel biologic product to reverse atherosclerotic plaque development and reduce the risk of coronary events in patients with ACS; and ALN-PCS, a development program for the treatment of hypercholesterolemia. In addition, it offers acute care generic products for use in the cardiovascular, neurocritical care, and serious infection therapeutic areas; and promotes BRILINTA, an oral tablet antiplatelet medicine. The company has collaboration agreements with Alnylam Pharmaceuticals, Inc. and AstraZeneca LP.

 

 

COMPANY ADDRESS
The Medicines Company
8 Sylvan Way
Parsippany, NJ 07054 U.S.A
United States

COMPANY PHONE
973-290-6000
Toll-free: 800-388-1183

COMPANY WEBSITE



Get BioInvest's perspective on the Medicines Company's CEO


Latest Company News

The Medicines Company (MDCO) Earning Somewhat Favorable News Coverage ... The Cerbat Gem - 8 hours ago The Medicines Company logo News headlines about The Medicines Company (NASDAQ:MDCO) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The Medicines Company (MDCO) Shares Bought by Legal & General Group Plc - Sports Perspectives Integer Holdings (ITGR) Reaches $43.25 52-Week High, The Medicines Company ... - High Point Observer [...]
Tue, Jun 27, 2017 12:56:00 PM, Continue reading at the source
Option Market Alert: The Medicines Company Implied Price Swing Hits A Notable High CML News - Jun 25, 2017 Risk Alert: Before we dive into any analysis we simply note that The Medicines Company (NASDAQ:MDCO) risk is elevated. We'll detail it below -- but that's the lede -- the option market is starting to flash those neon lights that signal "risk is rising ... [...]
Sun, Jun 25, 2017 9:33:00 PM, Continue reading at the source
Decision Time: The Medicines Company (NASDAQ:MDCO) Stock Technicals Hit ... CML News - Jun 24, 2017 Decision Time: The Medicines Company (NASDAQ:MDCO) now sits in the perhaps the most difficult technical position -- the stock has no urgency in its direction and that has left it at an inflection point. [...]
Sat, Jun 24, 2017 5:26:00 PM, Continue reading at the source
Successful Earnings Option Trading: The Medicines Company (NASDAQ:MDCO) CML News - Jun 24, 2017 As we look at The Medicines Company we note that a short put is one of the most common implementations of an option strategy, but the analysis completed when employing the short put often times lacks the necessary rigor especially surrounding earnings. [...]
Sat, Jun 24, 2017 4:07:00 PM, Continue reading at the source
The Case for and Against The Medicines Company (MDCO) StockNewsJournal - Jun 22, 2017 The Medicines Company (MDCO) is an interesting player in the Healthcare space, with a focus on Drugs - Generic. The stock has been active on the tape, currently trading at $38.83, up from yesterday's close by 3.55%. $30.51 Million in Sales Expected for The Medicines Company (MDCO) This Quarter - The Cerbat Gem Is Selling Stock Like The Medicines Company (MDCO) After Such Decline Winning ... - KL Daily [...]
Thu, Jun 22, 2017 6:22:00 PM, Continue reading at the source
Few Things investors Didn't Know About: The Medicines Company (MDCO), Workday ... StockNewsJournal - Jun 20, 2017 The Medicines Company (NASDAQ:MDCO) market capitalization at present is $2.76B at the rate of $37.77 a share. The firm's price-to-sales ratio was noted 18.88 in contrast with an overall industry average of 3.62. Public Employees Retirement Association of Colorado Continues to Hold Position ... - The Cerbat Gem The Medicines Company (MDCO) Receives News Impact Score of 0.19 - Stock Observer [...]
Tue, Jun 20, 2017 12:00:00 PM, Continue reading at the source
The Medicines Company Risk Points versus Health Care CML News - Jun 18, 2017 This is a scatter plot analysis of the critical risk points from the option market for The Medicines Company (NASDAQ:MDCO) compared to its own past and the Health Care ETF. [...]
Sun, Jun 18, 2017 8:37:00 PM, Continue reading at the source
2 Stocks to keep an eye on Today: The Medicines Company (MDCO), Intuit Inc. (INTU) StockNewsJournal - Jun 5, 2017 The Medicines Company (NASDAQ:MDCO) market capitalization at present is $2.87B at the rate of $40.19 a share. The firm's price-to-sales ratio was noted 20.46 in contrast with an overall industry average of 3.58. [...]
Mon, Jun 05, 2017 12:00:00 PM, Continue reading at the source
The Medicines Company (MDCO): What's the Story? StockNewsJournal - Jun 2, 2017 The Medicines Company (MDCO) is an interesting player in the Healthcare space, with a focus on Drugs - Generic. The stock has been active on the tape, currently trading at $39.71, down from yesterday's close by -0.15%. The Medicines Company (MDCO) Receives Daily News Sentiment Rating of 0.69 - The Cerbat Gem Does The Medicines Company (MDCO) Have Any Gas After Today's Huge Decline? - KL Daily [...]
Fri, Jun 02, 2017 7:18:00 PM, Continue reading at the source
The Medicines Company to Present Data at ASM Microbe 2017 on Infectious ... Business Wire (press release) - May 30, 2017 PARSIPPANY, N.J.--(BUSINESS WIRE)--The Medicines Company (NASDAQ:MDCO) today announced that data from its portfolio of antimicrobial products and late-stage product candidates will be featured in presentations at the American Society for ... [...]
Tue, May 30, 2017 8:26:00 PM, Continue reading at the source